Nasdaq News

Key PointsCipher Digital has 3.3 more gigawatts in its portfolio than Riot Platforms.

(RTTNews) - Richardson Electronics Ltd. (RELL), an engineering solutions company, announced a significant increase in profit for the first quarter of fiscal 2027, supported by higher sales across all business units. Looking ahead, the company said it projects fiscal 2027 to be an

(RTTNews) - Propanc Biopharma, Inc. (PPCB), a biopharmaceutical company, highlighted new preclinical data for its lead investigational candidate PRP in pancreatic ductal adenocarcinoma (PDAC) and compared that profile with a clinical standard recently established by Revolution Me

Key PointsIntel forecast an adjusted gross margin of around 42% for the third quarter, just over the second quarter's 41.8%.

(RTTNews) - Galderma (GALD), a dermatology-focused company, will present new long-term data for Nemluvio in patients with moderate-to-severe atopic dermatitis and prurigo nodularis at the 2026 Fall Clinical Dermatology Conference being held October 8-11 in Las Vegas, United State

Key PointsExperts anticipate a 3.5% to 3.6% COLA in 2027.

Fintel reports that on October 6, 2026, Raymond James upgraded their outlook for Old National Bancorp - Preferred Stock (NASDAQGS:ONBPP) from Market Perform to Outperform.Old National Bancorp, based in the United States, operates primarily in the banking industry. Headquartered i

(RTTNews) - Thursday, Bayer (BYR.L) announced that the U.S. FDA has accepted its supplemental New Drug Application (sNDA) for KERENDIA (finerenone) to treat adults with non-diabetic chronic kidney disease (CKD).

Key PointsKimberly-Clark is funding a $48.7 billion acquisition of Kenvue while continuing its 54-year streak of dividend increases.

(RTTNews) - Fast Retailing Co. (FRCOY) reported that, for the fiscal year ended August 31, 2026, profit attributable to owners of the parent company grew 25.3% to 542.52 billion yen, compared with 433.01 billion yen in the prior year. Diluted earnings per share was 1,765.70 yen c

(RTTNews) - argenx SE (ARGX), an immunology company, on Thursday reported positive Phase 2 results for FB102 in celiac disease and separately announced that it will discontinue the Phase 3 UNITY study of efgartigimod in Sjögren's disease.

(RTTNews) - Valneva SE (VALN), a speciality vaccine company, announced that after a further benefit-risk assessment of IXCHIQ for travellers by the United Kingdom's (UK) Commission on Human Medicines (CHM), the Medicines and Healthcare products Regulatory Agency (MHRA) revoked th

(RTTNews) - British retail major Tesco Plc (TSCO.L) reported Thursday strong first-half results and raised its fiscal 2027 profit outlook on the back of resilient consumer demand and operational improvements. Further, the firm raised share buyback program.

(RTTNews) - Aberdeen (ABDN.L) announced it has sold an aggregate of 52 million ordinary shares in Standard Life plc, representing approximately 5.2% of Standard Life's issued share capital, at a price of 839 pence per share, raising aggregate gross sale proceeds of approximately

Key PointsAlphabet trades at a forward price-to-earnings ratio of less than 23, despite being one of the highest-quality companies on Earth.

(RTTNews) - Glaukos Corporation (GKOS), an ophthalmic pharmaceutical and medical technology company, announced positive topline results from a long-term Phase 3 extension study (GLK-202-03) evaluating the durability, visual outcomes, and safety of Epioxa, the company's epi-on cor

(RTTNews) - HP Inc. (HPQ), a major IT company, said that it has expanded its portfolio of local AI solutions, spanning RTX Spark-powered consumer Windows PCs through workstation-class AI systems powered by NVIDIA GB300.

(RTTNews) - Thursday, Galderma (GALD.SW) presented new three-year data from the ARCADIA long-term extension study showing sustained improvements with Nemluvio (nemolizumab) in patients with atopic dermatitis (AD).

(RTTNews) - Hydro One Limited (H.TO), an electricity transmission and distribution company, said its unit Hydro One Networks Inc. has submitted its 2028-2032 Joint Rate Application to the Ontario Energy Board, proposing an approximately C$37 billion five-year investment plan.

(RTTNews) - argenx SE (ARGX) announced that it will discontinue the Phase 3 UNITY study of efgartigimod subcutaneous in adults with moderate-to-severe Sjgren's disease. Following interim analysis, an Independent Data Monitoring Committee concluded that the UNITY study is unable t